- Home
- RCKT vs MYGN Comparison
RCKT vs MYGN Comparison
Compare RCKT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | MYGN |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.6M | 444.2M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | RCKT | MYGN |
|---|---|---|
| Price | $3.14 | $2.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $29.73 | $7.64 |
| AVG Volume (30 Days) | ★ 1.8M | 978.5K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | $64.28 | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $2.53 | $3.53 |
| 52 Week High | $5.45 | $8.59 |
Technical Indicators
Market Signals| Indicator | RCKT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 23.12 |
| Support Level | $2.95 | N/A |
| Resistance Level | $3.63 | $5.17 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.06 | -0.26 |
| Stochastic Oscillator | 7.82 | 5.30 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.